Results 251 to 260 of about 69,107 (331)

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos S. Mantzoros   +4 more
wiley   +1 more source

Dipeptidyl peptidase 4 (DPP4), adipose inflammation, and insulin resistance: is it time to look to the hepatocyte?

, 2018
Wellington S. Silva Júnior, Maria das Graças Coelho de Souza, Luiz Guilherme Kraemer‐Aguiar   +2 more
openalex   +2 more sources

Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

, 2020
Fang Zhang, Shishi Xu, Lizhi Tang, Xiaohui Pan, Nanwei Tong   +4 more
openalex   +1 more source

The Causal Mechanism Between the Dipeptidyl Peptidase-4, Heart Failure, and Other Cardiovascular Diseases: A Mendelian Randomization and Mediation Study. [PDF]

Int J Endocrinol
Chen CK, Kuo CF, Chang YJ, Zhang W, Doherty M, Chang ML, Chen TH.   +6 more
europepmc   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitor Use with COVID-19 Mortality in Diabetic Patients: A Nationwide Cohort Study in Korea. [PDF]

J Clin Med
Park JW, Kwak MK, Park S, Heo NH, Lee EY.   +4 more
europepmc   +1 more source

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes

, 2020
Seiichi Ishii, Yoshio Nagai, Hiroyuki Kato, Hisashi Fukuda, Yasushi Tanaka   +4 more
openalex   +2 more sources

A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 205-213, February 2026.
Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, was evaluated in a Phase 1, double‐blind, placebo‐controlled, randomized, single and multiple ascending dose study in Japanese participants with type 2 diabetes. The safety and tolerability profile of orforglipron was consistent with those of other GLP‐1 receptor agonists, and ...
Kenji Ohwaki, Chino Nakamura, Risa Nasu, Kazumasa Takenouchi, Tetsuaki Hirase   +4 more
wiley   +1 more source

Dipeptidyl peptidase-4 enzyme inhibition and its impacts on hepatic preneoplasia: a new avenue for liver cancer management. [PDF]

Front Pharmacol
Eitah HE, Sayed RH, Maklad YA, Gamal El Din AA, Mahmoud K, El-Sahar AE, Alhejely A, Abdulbaqi AA, Naeim Attia H.   +8 more
europepmc   +1 more source

Dipeptidyl peptidase‐4 inhibitor approaches

Journal of Diabetes, 2016
openaire   +1 more source

Diabetic peripheral neuropathy as measured using a point‐of‐care sural nerve conduction device is associated with a faster decline in renal function in patients with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 291-300, February 2026.
Point‐of‐care assessment of diabetic peripheral neuropathy with DPN‐Check® was independently associated with a faster decline in renal function in type 2 diabetes, highlighting its potential as a tool to identify patients at high risk of kidney disease progression. ABSTRACT Aims/Introduction Diabetic peripheral neuropathy (DPN) is a common complication
Tatsuya Fukuda, Akiko Fujii, Taro Akihisa, Naoya Otsubo, Tetsuya Yamada, Chisato Maki   +5 more
wiley   +1 more source